We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA NEEDS TO EXPLAIN PROTECTIONS FOR GENOMIC DATA
FDA NEEDS TO EXPLAIN PROTECTIONS FOR GENOMIC DATA
January 30, 2004
The FDA needs to offer more detail on how the proprietary interests of drugmakers would be protected in its draft guidance on pharmacogenomics that calls for voluntary genomic data submissions (VGDSs), Eli Lilly told the agency in recent comments.